Brief: Inflarx To Announce Topline Data From Phase 2A Clinical Trial Of Inf904 In Hidradenitis Suppurativa And Chronic Spontaneous Urticaria
07/11/2025 22:07
InflaRx NV IF0G.F: INFLARX TO ANNOUNCE TOPLINE DATA FROM PHASE 2A CLINICAL TRIAL OF INF904 IN HIDRADENITIS SUPPURATIVA AND CHRONIC SPONTANEOUS URTICARIA Source text: ID:nGNX3t1P5L Further company coverage: IF0G.F
Recent news on Inflarx NV
See all newsBrief: Inflarx NV Files For Offerng Of Ordinary Shares, Size Not Disclosed - SEC Filing
Brief: InflaRx Reports Full Year 2025 Results And Highlights Key Achievements And Expected Milestones
Brief: Inflarx Announces Late-Breaker Oral Presentation On Vilobelimab Phase 3 Results In Pyoderma Gangrenosum At 2026 American Academy Of Dermatology Annual Meeting
Brief: Inflarx NV Executing 30% Workforce Reduction
Brief: Inflarx Provides Update On Phase 3 Data Analyses For Vilobelimab In Pyoderma Gangrenosum